Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) just added some new —...

Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) just added some new — and familiar — faces to its executive team.

The local vaccine maker said Monday it has appointed Jim Kelly, formerly chief financial officer of fellow Montgomery County biotech Supernus Pharmaceuticals Inc., as its new executive vice president, treasurer and CFO. The company also tapped Sanofi alum Nasir Egal as senior vice president of quality assurance.Kelly, who will report to Novavax President and CEO Stan Erck, has spent more than 25 years at commercial and clinical-stage companies. Prior to Supernus (NASDAQ: SUPN), which he joined in October 2020, Kelly spent a decade at D.C.’s Vanda Pharmaceuticals as CFO.

He also held posts at AstraZeneca PLC’s (NASDAQ: AZN) MedImmune and Cambridge, Massachusetts-based Biogen Inc. (NASDAQ: BIIB).Kelly assumes the slot at Novavax from John Trizzino — executive vice president, chief commercial officer and chief business officer for Novavax — who has also been serving as interim CFO for the company.Kelly joins Novavax at a pivotal moment for the homegrown biotech, which bounced back from the brink of collapse in its quest to deliver a Covid-19 vaccine and grew exponentially overnight — and is now looking to become a global commercial company, Erck said in a statement. “His experience will be of particular importance as we prepare to effectively deliver urgently needed vaccine to all corners of the world in the fight against Covid-19 and work to advance our pipeline of vaccine candidates targeting serious infectious diseases.”

Egal joins the Maryland company from French drugmaker Sanofi (NASDAQ: SNY), where he spent nearly a decade and most recently served as head of global quality external affairs. He’d previously held positions at global pharmaceutical giants Novartis International AG (NYSE: NVS) and Merck & Co. (NYSE: MRK), as well as with the Food and Drug Administration as a research scientist.At Novavax, he’ll report to Rick Crowley, executive vice president and chief operations officer.His perspectives and “invaluable quality expertise” will help Novavax as it looks to get its Covid vaccine across the regulatory finish line and to the world, Crowley said in a statement. We have reached out for additional details and will update this post as we hear back.The appointments are just the latest in a series of additions Novavax has made throughout the pandemic to its leadership team and board, bringing on industry expertise to continue its mammoth transformation.